Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | http://hdl.handle.net/1843/55418 |
Resumo: | COVID-19 is a deadly disease caused by the SARS-CoV-2 pandemic, which has remained a public health threat for over three years. In contrast to the severity of COVID-19, so far, there are few drugs capable of efficiently preventing or delaying the development of severe COVID-19. More importantly, studies focusing on compounds controlled intranasally to act more quickly in the airways and mucous membranes of individuals with severe COVID-19 under mechanical ventilation are still reduced. In this sense, BromAc® is a combination of bromelain and acetylcysteine (NAC), currently used for the treatment of pseudomyxoma (Phase 3) and has been studied for repositioning in the treatment of COVID-19. Therefore, in the present study, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® ex-vivo in a sample of tracheal aspirates from critically ill patients with COVID-19 under mechanical ventilation and the anti-inflammatory effect of BromAc® in an in vitro system using peripheral blood cells stimulated with inactivated SARS-CoV-2. Our results sadden that BromAc® exhibited a robust mucolytic effect in the exception of tracheal aspirates from patients with COVID-19 in a dose-dependent manner. In addition, BromAc® has demonstrated anti-inflammatory activity, reducing the cytokine storm in the tracheal aspirate samples from patients with COVID-19 and in culture supernatants. The combination showed reduced chemokines compared to NAC individually. The action of the combined compounds on regulatory cytokines such as IL-10 was also observed. Furthermore, BromAc® was able to modulate CD16+ and CD14+ cells after in vitro treatment of blood cells with BromAc®. These results indicate a robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill patients, indicating its potential as a therapeutic strategy for COVID-19. Clinical trials are needed to define the safety and efficacy of BromAc® in the treatment of the disease, which has been the greatest challenge of the 21st century. |
id |
UFMG_77bbca5dff15f1672835f13923d7e5e9 |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/55418 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19Evaluation of the mucolytic and anti-inflammatory activity of BromAc® applied to the treatment of COVID-19MicrobiologiaCOVID-19BromelaínasAcetilcisteínaMicrobiologiaCovid-19BromelaínasAcetilcisteínaCOVID-19 is a deadly disease caused by the SARS-CoV-2 pandemic, which has remained a public health threat for over three years. In contrast to the severity of COVID-19, so far, there are few drugs capable of efficiently preventing or delaying the development of severe COVID-19. More importantly, studies focusing on compounds controlled intranasally to act more quickly in the airways and mucous membranes of individuals with severe COVID-19 under mechanical ventilation are still reduced. In this sense, BromAc® is a combination of bromelain and acetylcysteine (NAC), currently used for the treatment of pseudomyxoma (Phase 3) and has been studied for repositioning in the treatment of COVID-19. Therefore, in the present study, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® ex-vivo in a sample of tracheal aspirates from critically ill patients with COVID-19 under mechanical ventilation and the anti-inflammatory effect of BromAc® in an in vitro system using peripheral blood cells stimulated with inactivated SARS-CoV-2. Our results sadden that BromAc® exhibited a robust mucolytic effect in the exception of tracheal aspirates from patients with COVID-19 in a dose-dependent manner. In addition, BromAc® has demonstrated anti-inflammatory activity, reducing the cytokine storm in the tracheal aspirate samples from patients with COVID-19 and in culture supernatants. The combination showed reduced chemokines compared to NAC individually. The action of the combined compounds on regulatory cytokines such as IL-10 was also observed. Furthermore, BromAc® was able to modulate CD16+ and CD14+ cells after in vitro treatment of blood cells with BromAc®. These results indicate a robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill patients, indicating its potential as a therapeutic strategy for COVID-19. Clinical trials are needed to define the safety and efficacy of BromAc® in the treatment of the disease, which has been the greatest challenge of the 21st century.A COVID-19 é uma doença letal causada pela pandemia SARS-CoV-2, que permanece uma ameaça à saúde pública há mais de três anos. Em contraste com a gravidade do COVID-19, até o momento, existem poucos medicamentos capazes de prevenir ou retardar o desenvolvimento do COVID-19 grave de forma eficiente. Mais importante, ainda são escassos os estudos com foco em compostos administradas por via intranasal para agir mais rapidamente nas vias aéreas e muco de indivíduos com COVID-19 grave sob ventilação mecânica. Nesse sentido, BromAc® é uma combinação de bromelina e acetilcisteína (NAC), atualmente utilizada para o tratamento de pseudomixoma (Fase 3) e tem sido estudada para o reposicionamento no tratamento de COVID-19. Portanto, no presente estudo, procurou-se examinar o efeito mucolítico e anti-inflamatório do BromAc® ex-vivo em amostras de aspirado traqueal de pacientes críticos com COVID-19 sob ventilação mecânica e o efeito anti-inflamatório de BromAc® em um sistema in vitro utilizando células do sangue periférico estimuladas com o SARS-CoV-2 inativado. Nossos resultados demonstraram que o BromAc® exibiu um efeito mucolítico robusto em amostras de aspirado traqueal de pacientes com COVID-19 de maneira dose-dependente. Além disso, o BromAc® demonstrou atividade anti-inflamatória, reduzindo a ação da tempestade de citocinas em amostras de aspirado traqueal de pacientes com COVID-19 e nos sobrenadantes de cultura. A combinação apresentou redução de quimiocinas, em comparação com NAC isoladamente. Foi também observado a ação dos compostos combinados sobre citocinas reguladoras como IL-10. Além disso, o BromAc® foi capaz de modular as populações celulares CD16+ e CD14+ após o tratamento in vitro de células sanguíneas com BromAc®. Esses resultados indicam um efeito mucolítico e anti-inflamatório robusto do BromAc® em aspirados traqueais de pacientes críticos, indicando seu potencial como estratégia terapêutica para o COVID-19. Ensaios clínicos são necessários para definir a segurança e a eficácia do BromAc® no tratamento da doença, que tem sido o maior desafio do século XXI.CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorUniversidade Federal de Minas GeraisBrasilICB - DEPARTAMENTO DE MICROBIOLOGIAPrograma de Pós-Graduação em MicrobiologiaUFMGJordana Grazziela Alves Coelho dos Reishttp://lattes.cnpq.br/0775593522993297Geovane Marques Ferreira2023-06-27T16:55:01Z2023-06-27T16:55:01Z2023-04-17info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/1843/55418porinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMG2023-06-27T16:55:01Zoai:repositorio.ufmg.br:1843/55418Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2023-06-27T16:55:01Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.none.fl_str_mv |
Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19 Evaluation of the mucolytic and anti-inflammatory activity of BromAc® applied to the treatment of COVID-19 |
title |
Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19 |
spellingShingle |
Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19 Geovane Marques Ferreira Microbiologia COVID-19 Bromelaínas Acetilcisteína Microbiologia Covid-19 Bromelaínas Acetilcisteína |
title_short |
Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19 |
title_full |
Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19 |
title_fullStr |
Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19 |
title_full_unstemmed |
Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19 |
title_sort |
Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19 |
author |
Geovane Marques Ferreira |
author_facet |
Geovane Marques Ferreira |
author_role |
author |
dc.contributor.none.fl_str_mv |
Jordana Grazziela Alves Coelho dos Reis http://lattes.cnpq.br/0775593522993297 |
dc.contributor.author.fl_str_mv |
Geovane Marques Ferreira |
dc.subject.por.fl_str_mv |
Microbiologia COVID-19 Bromelaínas Acetilcisteína Microbiologia Covid-19 Bromelaínas Acetilcisteína |
topic |
Microbiologia COVID-19 Bromelaínas Acetilcisteína Microbiologia Covid-19 Bromelaínas Acetilcisteína |
description |
COVID-19 is a deadly disease caused by the SARS-CoV-2 pandemic, which has remained a public health threat for over three years. In contrast to the severity of COVID-19, so far, there are few drugs capable of efficiently preventing or delaying the development of severe COVID-19. More importantly, studies focusing on compounds controlled intranasally to act more quickly in the airways and mucous membranes of individuals with severe COVID-19 under mechanical ventilation are still reduced. In this sense, BromAc® is a combination of bromelain and acetylcysteine (NAC), currently used for the treatment of pseudomyxoma (Phase 3) and has been studied for repositioning in the treatment of COVID-19. Therefore, in the present study, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® ex-vivo in a sample of tracheal aspirates from critically ill patients with COVID-19 under mechanical ventilation and the anti-inflammatory effect of BromAc® in an in vitro system using peripheral blood cells stimulated with inactivated SARS-CoV-2. Our results sadden that BromAc® exhibited a robust mucolytic effect in the exception of tracheal aspirates from patients with COVID-19 in a dose-dependent manner. In addition, BromAc® has demonstrated anti-inflammatory activity, reducing the cytokine storm in the tracheal aspirate samples from patients with COVID-19 and in culture supernatants. The combination showed reduced chemokines compared to NAC individually. The action of the combined compounds on regulatory cytokines such as IL-10 was also observed. Furthermore, BromAc® was able to modulate CD16+ and CD14+ cells after in vitro treatment of blood cells with BromAc®. These results indicate a robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill patients, indicating its potential as a therapeutic strategy for COVID-19. Clinical trials are needed to define the safety and efficacy of BromAc® in the treatment of the disease, which has been the greatest challenge of the 21st century. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-06-27T16:55:01Z 2023-06-27T16:55:01Z 2023-04-17 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/55418 |
url |
http://hdl.handle.net/1843/55418 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil ICB - DEPARTAMENTO DE MICROBIOLOGIA Programa de Pós-Graduação em Microbiologia UFMG |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil ICB - DEPARTAMENTO DE MICROBIOLOGIA Programa de Pós-Graduação em Microbiologia UFMG |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
repositorio@ufmg.br |
_version_ |
1823248244846624768 |